1 Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy
2 Specialist Biologist in Genetics, Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), ULSS 8 BERICA, San Bortolo Hospital, San Bortolo, Vicenza, Italy
3 Udine University Hospital, DAME, Udine, Italy
4 Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiology, Thoracic and Vascular Sciences, University of Padova, Padova, Italy
5 Laboratory of Clinical Analysis, San Bortolo Hospital, Vicenza, Italy
Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy
Specialist Biologist in Genetics, Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), ULSS 8 BERICA, San Bortolo Hospital, San Bortolo, Vicenza, Italy
Acute rejection (AR) is one of the most frequent complications after kidney transplantation (KT). Scientific evidence reports that some single-nucleotide polymorphisms (SNPs) located in genes involved in the immune response and in the pharmacokinetics and pharmacodynamics of immunosuppressive drugs are associated with rejection in renal transplant patients. The aim of this study was to evaluate some SNPs located in six genes: interleukin-10 (IL-10), tumor necrosis factor (TNF), adenosine triphosphate-binding cassette sub-family B member 1 (ABCB1), uridine diphosphate glucuronosyltransferase family 1 member A9 (UGT1A9), inosine monophosphate dehydrogenase 1 (IMPDH1) and IMPDH2.
We enrolled cases with at least one AR after KT and two groups of controls: patients without any AR after KT and healthy blood donors. Genetic analysis on DNA was performed. The heterozygosity (HET) was determined and the Hardy-Weinberg equilibrium (HWE) test was performed for each SNP. The sample size was calculated using the QUANTO program and the genetic associations were calculated using the SAS program (SAS Institute Inc., Cary, NC, USA).
In our previous preliminary study (sample size was not reached for cases), the results showed that patients with the C allele in the SNP rs1045642 and the A allele in the SNP rs2032582 of the ABCB1 gene had more frequent AR. In contrast, with the achievement of sample size, the trend of the previous data was not confirmed.
Our study highlights a fundamental aspect of scientific research that is generally presumed, i.e. the sample size of groups enrolled for a scientific study. We believe that our study will make a significant contribution to the scientific community in the discussion of the importance of the analysis and the achievement of sample size to evaluate the associations between SNPs and the studied event.
Wang Z, Yang H, Si S, Han Z, Tao J, Chen H, et al. Polymorphisms of nucleotide factor of activated T cells cytoplasmic 2 and 4 and the risk of acute rejection following kidney transplantation. World J Urol 2018;36:111–6.
Eskandari SK, Seelen MA, Lin G, Azzi JR. The immunoproteasome: an old player with a novel and emerging role in alloimmunity. Am J Transplant 2017;17:3033–9.
Matas AJ, Hays RE, Ibrahim HN. Long-term non-end-stage renal disease risks after living kidney donation. Am J Transplant 2017;17:893–900.
Williams WW, Taheri D, Tolkoff-Rubin N, Colvin RB. Clinical role of the renal transplant biopsy. Nat Rev Nephrol 2012;8:110–21.
Ponticelli C. Chapter 4: Acute rejection. In: Medical complications of kidney transplantation. London: Informa Healthcare, 2007:85–104. ISBN 10-0-415-41715-5.
Fekete A, Viklicky O, Hubacek JA, Rusai K, Erdei G, Treszl A, et al. Association between heat shock protein 70s and toll-like receptor polymorphisms with long-term renal allograft survival. Transpl Int 2006;19:190–6.
Grinyo J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 2008;21:879–91.
Kruger B, Boger CA, Schroppel B, Obed A, Hoffmann U, MurphyBT, et al. Impact of NOD2/CARD15 haplotypes on the outcome after kidney transplantation. Transpl Int 2007;20:600–7.
Marder B, Schroppel B, Murphy B. Genetic variability and transplantation. Curr Opin Urol 2003;13:81–9.
Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001;72:1444–50.
Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003;75:711–7.
Scalzotto E, Corradi V, Salin A, Caprara C, Skoumal, Neri A, et al. Single nucleotide polymorphism profiles of patients with acute renal rejection to personalize immunosuppressive therapy: preliminary results from an on-going, Italian study. J Organ Transpl 2017;1:17–31.
Kang DH, Yu ES, Yoon KI, Johnson R. The impact of gender on progression of renal disease: potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection. Am J Pathol 2004;164:679–88.
Pratschke J, Merk V, Reutzel-Selke A, Pascher A, DeneckeC, LunA, et al. Potent early immune response after kidney transplantation in patients of the European Senior Transplant Program. Transplantation 2009;87:992–1000.
Guillen-Gomez E, Guirado L, Belmonte X, Maderuelo A, Santin S, Juarez C, et al. Monocyte implication in renal allograft dysfunction. Clin Exp Immunol 2014;175:323–31.
Rashad Hassan R, Khaled MM, Amgad EE, Ahmed FH, Amani MI, Nagy A, et al. Gene polymorphism and graft outcome in live-donor kidney transplantation. Afr J Nephrol 2016;19:6–13.
Xiong J, Wang Y, Zhang Y, Nie L, Wang D, Huang Y, et al. Lack of association between interleukin-10 gene polymorphisms and graft rejection risk in kidney transplantation recipients: a meta-analysis. PLoS One 2015;10:e0127540.
Chen Z, Bouamar R, Van Schaik RH, De Fijter JW, Hartmann A, Zeier M, et al. Genetic polymorphisms in IL-2, IL-10, TGF-beta1, and IL-2RB and acute rejection in renal transplant patients. Clin Transpln 2014;28:649–55.
Azarpira N, Aghdai MH, Raisjalali GA, Darai M, Tarahi MJ. Influence of recipient and donor IL-10, TNFA and INFG genotypes on the incidence of acute renal allograft rejection. Mol Biol Rep 2009;36:1621–6.
Azarpira N, Aghdaie MH, Geramizadeh B, Behzadi S, Nikeghbalian S, Sagheb F, et al. Cytokine gene polymorphisms in renal transplant recipients. Exp Clin Transpl 2006;4: 528–31.
Brabcova I, Petrasek J, Hribova P, Hyklova K, Bartosova K, LachaJ, et al. Genetic variability of major inflammatory mediators has no impact on the outcome of kidney transplantation. Transplantation 2007;84:1037–44.
Fukuda T, Goebel J, Cox S, Maseck D, Zhang K, Sherbotie JR, et al. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther Drug Monit 2012;34:671–9.
Mazidi T, Rouini MR, Ghahremani MH, Dashti-Khavidaki S, Lessan-Pezeshki M, Ahmadi FL, et al. Impact of UGT1A9 polymorphism on mycophenolic acid pharmacokinetic parameters in stable renal transplant patients. Iran J Pharm Res 2013;12:547–56.
Xie XC, Li J, Wang HY, Li HL, Liu J, Fu Q, et al. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients. Acta Pharmacol Sin 2015;36:644–50.
Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE. PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genom 2014;24:73–9.
Woillard JB, Picard N, Thierry A, Touchard G, Marquet P. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet Genomics 2014;24:256–62.
Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008;83:711–7.
Llaudo I, Colom H, Gimenez-Bonafe P, Torras J, Caldes A, Sarrias M, et al. Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. Transpl Int 2013;26:177–86.
Crettol S, Venetz JP, Fontana M, Aubert JD, Ansermot N, Fathi M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics 2008;18:307–15.
Falck P, Asberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet JL, et al. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. Transplantation 2008;85:179–84.
Zheng HX, Zeevi A, McCurry K, Schuetz E, Webber S, Ristich J, et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol 2005;14:37–42.
Zhong X, Liu MY, Sun XH, Wei MJ. Association between ABCB1 polymorphisms and haplotypes and Alzheimer’s disease: a meta-analysis. Sci Rep 2016;6:32708.
Diagnosis aims at answering the question how diagnosis determines the quality of medical care. It focuses on how diagnosis can be advanced, how it is taught, and how and why it can fail, leading to diagnostic errors. The journal welcomes both fundamental and applied works, improvement initiatives, opinions, and debates to encourage new thinking on improving this critical aspect of healthcare quality.